World's Best Scientists 2026 revealed!
Xavier Thomas

Xavier Thomas

D-Index & Metrics

Medicine

D-Index
90
Citations
31079
World Ranking
12171
National Ranking
6241

Xavier Thomas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Xavier Thomas sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 691 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Xavier Thomas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Xavier Thomas sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Xavier Thomas is affiliated with Lyon College in the United States and has a substantial body of work primarily within the medical sciences. Their research output is concentrated in the field of Medicine, with 196 publications. Within this broad area, the main subfields include Hematology, Molecular Biology, Genetics, Public Health, Environmental and Occupational Health, and Oncology.

Their research extensively covers topics related to leukemia and related hematological conditions. The main topics of Thomas's work include:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Histone Deacetylase Inhibitors Research
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors

Frequent collaborators in their publications comprise several researchers with repeated co-authorship, emphasizing collaborative efforts in the field. These co-authors include Christian Récher, Hervé Dombret, Arnaud Pigneux, Emmanuel Raffoux, and Nicolas Boissel.

Thomas has published multiple papers in a variety of scientific journals, with a notable concentration in venues such as Blood and Blood Advances. Other frequent publication venues include Clinical Lymphoma Myeloma & Leukemia, Leukemia, and Oncology and Therapy.

Significant recent papers authored or co-authored by Thomas demonstrate a focus on clinical and therapeutic studies in acute myeloid leukemia (AML) and related areas. Some of these include:

  • "Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML" (2023, Blood Advances)
  • "Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort" (2021, Blood Advances)
  • "Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial" (2022, Blood)
  • "Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients" (2021, Nature Communications)
  • "Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results" (2020, Blood Advances)

The research activities reflect a blend of clinical trials, genetic and molecular studies, as well as investigations into the microbiota's role in leukemia treatment outcomes, indicating multidisciplinary approaches to addressing hematological malignancies.

Best Publications

  • Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding

  • Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Hagop M. Kantarjian;Xavier G. Thomas;Anna Dmoszynska;Agnieszka Wierzbowska

  • Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

    Sylvie Castaigne;Cécile Pautas;Christine Terré;Emmanuel Raffoux

  • Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials

    Nicolas Boissel;Marie-Françoise Auclerc;Véronique Lhéritier;Yves Perel

  • Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

    Françoise Huguet;Thibaut Leguay;Emmanuel Raffoux;Xavier Thomas

  • OUTCOME OF TREATMENT IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: ANALYSIS OF THE LALA-94 TRIAL

    Xavier Thomas;Jean Michel Boiron;Françoise Huguet;Hervé Dombret

  • Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.

    Hervé Dombret;Jean Gabert;Jean-Michel Boiron;Françoise Rigal-Huguet

  • Incidence and prognostic impact of c-Kit , FLT3 , and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)

    N Boissel;H Leroy;B Brethon;N Philippe

  • Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

    Céline Berthon;Emmanuel Raffoux;Xavier Thomas;Norbert Vey

  • Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

    Yves Chalandon;Xavier Thomas;Sandrine Hayette;Jean-Michel Cayuela

  • Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

    Eric Jourdan;Nicolas Boissel;Sylvie Chevret;Eric Delabesse

  • Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

    Sébastien Maury;Sylvie Chevret;Xavier Thomas;Dominik Heim

  • Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

    Kheira Beldjord;Sylvie Chevret;Vahid Asnafi;Françoise Huguet

  • Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

    Lionel Adès;Lionel Adès;Agnes Guerci;Emmanuel Raffoux;Miguel Sanz

  • Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

    Juliette Lambert;Cécile Pautas;Christine Terré;Emmanuel Raffoux

  • High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

    A.-L. Taksin;O. Legrand;E. Raffoux;T. De Revel

  • Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

    Marie Balsat;Aline Renneville;Xavier Thomas;Stéphane de Botton

  • NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.

    Vahid Asnafi;Vahid Asnafi;Agnès Buzyn;Sandrine Le Noir;Sandrine Le Noir;Frédéric Baleydier;Frédéric Baleydier

  • Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

    Nathalie Dhédin;Anne Huynh;Sébastien Maury;Reza Tabrizi

  • Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

    Nicolas Boissel;Aline Renneville;Valeria Biggio;Nathalie Philippe

Frequent Co-Authors

Claude Preudhomme
Claude Preudhomme University of Lille
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Emmanuel Raffoux
Emmanuel Raffoux Hôpital Saint-Louis
Hervé Dombret
Hervé Dombret Université Paris Cité
Sylvie Castaigne
Sylvie Castaigne Versailles Saint-Quentin-en-Yvelines University
Mauricette Michallet
Mauricette Michallet University of Helsinki
Christian Recher
Christian Recher Federal University of Toulouse Midi-Pyrénées
Nicolas Boissel
Nicolas Boissel Université Paris Cité
Sylvie Chevret
Sylvie Chevret Université Paris Cité
Aline Renneville
Aline Renneville Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens a variety of online degree options for those interested in healthcare careers. Prospective nurses may choose rn to bsn online no clinicals programs, which provide flexibility for working RNs to earn their bachelor’s degree without additional on-site requirements.

For nurses aiming to advance to leadership or specialized clinical roles, there are several online dnp programs available that offer accelerated paths to a Doctor of Nursing Practice degree. Budget-conscious students can look for affordable dnp programs, designed to lessen the financial burden while maintaining academic quality.

Additionally, those looking for a quick entry into the nursing field may consider a 6 month lpn program, which provides fast-track training to become a Licensed Practical Nurse. With such a wide array of online health degrees, individuals can find flexible opportunities to match their career goals and schedules.

Best Scientists Citing Xavier Thomas

Trending Scientists

Recently Published Articles